TMEFF2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of TMEFF2. The page also collects GeneMedi's different modalities and formats products for TMEFF2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TMEFF2 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a member of the tomoregulin family of transmembrane proteins. This protein has been shown to function as both an oncogene and a tumor suppressor depending on the cellular context and may regulate prostate cancer cell invasion. Multiple soluble forms of this protein have been identified that arise from both an alternative splice variant and ectodomain shedding. Additionally, this gene has been found to be hypermethylated in multiple cancer types. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]
Target ID | GM-MP1810 |
Target Name | TMEFF2 |
Gene ID | 23671,56363,363228,694555,478848,101085308,538354,100054833 |
Gene Symbol and Synonyms | 4832418D20Rik,7630402F16Rik,CT120.2,HPP1,TENB2,TMEFF2,TPEF,TR,TR-2 |
Uniprot Accession | Q9UIK5,Q17QD6 |
Uniprot Entry Name | TEFF2_HUMAN,TEFF2_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Cytokine Target |
Disease | Esophagus Cancer |
Gene Ensembl | ENSG00000144339 |
Target Classification | N/A |
Pre-made anti-TMEFF2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-TMEFF2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TMEFF2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-TMEFF2 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Cytokine antibody | Detail |
Multi-species TEFF2/ TMEFF2/ CT120.2 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TMEFF2 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
TMEFF2 VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse Transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the tomoregulin family of transmembrane proteins. This protein has been shown to function as both an oncogene and a tumor suppressor depending on the cellular context and may regulate prostate cancer cell invasion. Multiple soluble forms of this protein have been identified that arise from both an alternative splice variant and ectodomain shedding. Additionally, this gene has been found to be hypermethylated in multiple cancer types. Alternative splicing results in multiple transcript variants.
Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
TMEFF2 | Human, Cynomolgus/Rhesus macaque, rat, mouse | Transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-TMEFF2 monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products
Pre-made TMEFF2 viral vector in GM Promise-ORFTM
Cat No. | Products name | NM ID | Species | Type | Detail |
vGMLP001589 | human TMEFF2 Lentivirus particle | NM_016192 | Human | Lentivirus particle | Detail |
pGMLP001589 | human TMEFF2 Lentivirus plasmid | NM_016192 | Human | Lentivirus plasmid | Detail |
pGMLPm002930 | mouse Tmeff2 Lentivirus plasmid | NM_019790 | Mouse | Lentivirus plasmid | Detail |
vGMLPm002930 | mouse Tmeff2 Lentivirus particle | NM_019790 | Mouse | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.